SML2283
来那度胺
≥98% (HPLC), powder, cereblon binder
别名:
来那度胺, 1-氧-4-氨基-2-(2,6-二氧哌啶-3-基)异吲哚, 3-(4-氨基-1,3-二氢-1-氧代-2H-异吲哚-2-基)-2,6-哌啶二酮, 3-(4-氨基-1-氧代异吲哚-2-基)哌啶-2,6-二酮, CC 5013, CC-5013
登录 查看组织和合同定价。
选择尺寸
关于此项目
经验公式（希尔记法）:
C13H13N3O3
化学文摘社编号:
分子量:
259.26
NACRES:
NA.77
UNSPSC Code:
12352200
MDL number:
Assay:
≥98% (HPLC)
Form:
powder
产品名称
来那度胺, ≥98% (HPLC)
InChI
1S/C13H13N3O3/c14-9-3-1-2-7-8(9)6-16(13(7)19)10-4-5-11(17)15-12(10)18/h1-3,10H,4-6,14H2,(H,15,17,18)
SMILES string
O=C1N(C2CCC(NC2=O)=O)CC3=C1C=CC=C3N
InChI key
GOTYRUGSSMKFNF-UHFFFAOYSA-N
ligand
lenalidomide
assay
≥98% (HPLC)
form
powder
reaction suitability
reagent type: ligand
color
white to beige
solubility
DMSO: 2 mg/mL, clear
storage temp.
2-8°C
正在寻找类似产品? 访问 产品对比指南
Biochem/physiol Actions
来那度胺，沙利度胺的一种衍生物，是经批准可用于治疗多发性骨髓瘤的一种免疫调节剂。显然，来那度胺是泛素E3连接酶cereblon的一种配体，可诱导该酶降解Ikaros转录因子IKAROS家族锌指1（IKZF1）和IKZF3。来那度胺具有多效抗肿瘤作用。它可用于治疗5q缺失相关骨髓增生异常综合症（del(5q)-MDS）。
signalword
Danger
hcodes
Hazard Classifications
Repr. 1B - STOT RE 2
target_organs
Blood
存储类别
6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
Hila Shaim et al.
Frontiers in immunology, 8, 1773-1773 (2018-01-31)
Chronic lymphocytic leukemia (CLL) cells possess regulatory functions comparable to those of normal B10 cells, a regulatory B cell subset that suppresses effector T-cell function through STAT3-mediated IL-10 production. However, the mechanisms governing IL-10 production by CLL cells are not
Yuan Xiao Zhu et al.
Blood, 118(18), 4771-4779 (2011-08-24)
The precise molecular mechanism of action and targets through which thalidomide and related immunomodulatory drugs (IMiDs) exert their antitumor effects remains unclear. We investigated the role of cereblon (CRBN), a primary teratogenic target of thalidomide, in the antimyeloma activity of
Thalidomide promotes degradation of SALL4, a transcription factor implicated in Duane Radial Ray syndrome
Donovan KA, et al.
eLife, 7, e38430-e38430 (2018)
Georg Petzold et al.
Nature, 532(7597), 127-130 (2016-02-26)
Thalidomide and its derivatives, lenalidomide and pomalidomide, are immune modulatory drugs (IMiDs) used in the treatment of haematologic malignancies. IMiDs bind CRBN, the substrate receptor of the CUL4-RBX1-DDB1-CRBN (also known as CRL4(CRBN)) E3 ubiquitin ligase, and inhibit ubiquitination of endogenous
Li Du et al.
Cancer gene therapy (2022-03-27)
Despite the potent effect of lenalidomide (Len) in multiple myeloma (MM) treatment, patients develop Len resistance leading to progressive disease, demanding an urgent need to investigate the mechanisms mediating Len resistance. Our study identified SUMOylation as a potential mechanism regulating
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持